luisreyes (2)Luis Reyes

Luis Reyes has more than 35 years of nuclear experience and has served in various Nuclear Regulatory Commission senior management positions. During his tenure at the NRC, the commission’s budget was significantly increased, and the commission consistently received the highest rating on its Government Performance Assessment review. He also served as executive-on-loan to the U.S. Department of Energy (DOE) to conduct a nuclear safety review at the request of the DOE Assistant Secretary. He was an expert consultant to the International Atomic Energy Agency (IAEA) in the area of operations experience, new nuclear plant construction and regulatory organizations. On behalf of the IAEA, Reyes led a team of international experts in the review of the regulatory organization of a European country.

He has received honors and awards that include the Presidential Distinguished Rank award and the Presidential Meritorious Rank award, which he was awarded three times. These awards are distributed by the President of the United States to a small group of career senior executives and senior career employees. Reyes earned a Bachelor of Science in electrical engineering and a Master of Science in nuclear engineering from the University of Puerto Rico-Mayaguez. He also attended the Federal Executive Institute at the Harvard University Kennedy School of Government.

welsh_jamesDr. James Welsh

James Welsh, MS, MD, FACRO, is a board certified radiation oncologist and neuro-oncologist, and has been a member of the Advisory Committee on the Medical Uses of Isotopes, which advises the Unites States Nuclear Regulatory Commission on medical issues, from 2007-2014. He obtained a master’s degree in molecular biophysics and biochemistry at Yale University and his M.D. at the State University of New York at Stony Brook. Dr. Welsh completed his residency training at The Johns Hopkins Hospital and stayed on at the Johns Hopkins faculty as an Assistant Professor of Oncology until 2001. Subsequently, he completed a fellowship at the University of Wisconsin investigating helical TomoTherapy, a newly developed form of image-guided, intensity-modulated radiotherapy technology. He joined the faculty at the University of Wisconsin and became Clinical Professor of Human Oncology and Medical Physics before briefly heading down South and serving as Professor of Neurosurgery and Radiology at the Louisiana State University School of Medicine–Shreveport and as a radiation oncologist at Willis-Knighton Hospital. Dr. Welsh returned to the Midwest as the fast neutron therapy physician at the Northern Illinois University Institute for Neutron Therapy at Fermilab and is now Professor, Medical Director, Director of Clinical & Translational Research Department of Radiation Oncology Stritch School of Medicine at Loyola University-Chicago and Chief of Radiation Oncology at the Hines VA Medical Center. He is currently president-elect of the American College of Radiation Oncology and sits on the editorial boards for several scientific and medical journals.

matte (2)Michael Matte

Michael Matte has served as the Chief Financial Officer, Executive Vice President, and Secretary of QuePasa Corp. since October 29, 2007. He is also a director of Iris International, Inc., and GelTech Solutions, Inc. From July 2006 through October 2007, Matte served as a director of QuePasa, and from February 2001 to April 2006, as Chief Financial Officer of Cyberguard Corp. Prior to joining Cyberguard, Matte was a senior audit manager from 1981 to 1992 for Price Waterhouse.

Pedro Serrano-Ojeda for bio (2)Dr. Pedro Serrano-Ojeda

Dr. Pedro Serrano-Ojeda, M.D., is a certified radiation oncologist that founded Caribbean Radiation Oncology Center in 2007 in Puerto Rico. He expanded the company a few years later with the announcement of its first facility outside of the island in Doral, Florida, that will open in spring 2015.

Dr. Serrano-Ojeda received his medical degree from the Ponce School of Medicine & Health Sciences. During his residency at the Medical College of Wisconsin, he studied under the guidance of prominent medical professionals such as Dr. Frank Wilson, the protégé of the legendary radiation oncologist Dr. Juan Del Regato. In 2009, Caribbean Radiation Oncology Center’s quality control data of the facility’s first 264 patients was published in the Medical Physics journal. It was the largest study at the time

Dr. Serrano-Ojeda has spoken at conferences throughout the U.S. and Latin America on behalf of TomoTherapy and Accuray, the manufacturer of the TomoTherapy technology, to offer insight on his experience with the machines and to teach techniques.

Ian Turner resizedIan Turner

Ian Turner is a successful CEO with prodigious international experience in high technology industries, specializing in the leadership of global organizations undergoing change. He has a record of corporate success in radiopharmaceuticals, nuclear industries, life sciences and medical devices.

Most recently, Turner served as CEO and President at Siemens where he was responsible for the global PETNET and Cyclotron businesses. PETNET operates the largest PET radiopharmaceutical network in the world with over 55 radiopharmacies in seven countries.

Previously, Turner was responsible for the radiopharmaceuticals business of the Australian Nuclear Science and Technology Organisation (ANSTO) in Australia, which is home to the OPAL (Open Pool Australian Lightwater) nuclear reactor from INVAP. He successfully created and led the initiative for ANSTO to be the first international commercial supplier of Molybdenum-99 derived from low-enriched uranium. He also served on the Organisation for Economic Co-operation and Development (OECD) High-level Group on the Security of Supply of Medical Radioisotopes.

Turner has master’s and bachelor’s degrees in electronic engineering from RMIT University and has a Company Directors Diploma from the AICD. He is a sought-after public speaker and global authority on PET and SPECT Radiopharmaceuticals. He has served on various boards in different countries, and he also consults for private equity firms. He is well published and has a number of patents.